Percentage of positive prostate biopsies independently predicts biochemical outcome following radiation therapy for prostate cancer

This work aims to definitely show the ability of Percentage of Positive Biopsy Cores (%PC) to independently predict biochemical outcome beyond traditional pre-treatment risk-factors in prostate cancer patients treated with radiotherapy.

A cohort of 2493 men belonging to the EUREKA-2 retrospective multi-centric database on prostate cancer and treated with External-Beam Radiation Therapy (EBRT) as primary treatment comprised the study population (median follow-up 50 months) A Cox regression time to PSA failure analysis was performed to evaluate the predictive power of %PC, both in univariate and multivariate settings, with age, pre-treatment PSA, clinical-radiological Staging, bioptic Gleason Score (bGS), RT dose and RT +/- ADT as covariates

P statistics for %PC is lower than 0 001 both in univariate and multivariate models %PC as a continuous variable yields an AUC of 69% in ROC curve analysis for biochemical relapse Four classes of %PC (1-20%, 21-50%, 51-80% and 81-100%) distinctly split patients for risk of biochemical relapse (overall log-rank test P

We strongly affirm the usefulness of %PC information beyond main risk factors (PSA, Staging and bGS) in predicting biochemical recurrence after EBRT for prostate cancer The stratification of patients according to %PC may be valuable to further discriminate cases with favourable or adverse prognosis

Panminerva medica 2015 Jul 24 [Epub ahead of print]

D Gabriele, M Garibaldi, G F Girelli, S Taraglio, E Duregon, P Gabriele, C Guiot, E Bollito

Neuroscience Department, Human Physiology Section, University of Torino, Italy - gabrielepda@alice it



Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.